20-F: XORTX Therapeutics Inc. Files 20-F, Highlights Gout Program and FDA Interactions

XORTX Therapeutics Inc. files its 20-F report, outlining financial performance and progress in its drug development programs, particularly highlighting the XRx-026 gout treatment and interactions with the FDA.

Summary

• XORTX Therapeutics Inc. has filed its 20-F report for the fiscal year ended December 31, 2024.
• The company is focused on developing therapies for gout, ADPKD, T2DN, and AKI associated with respiratory virus infections.
• A key focus is the XRx-026 program for gout, with plans to submit an NDA following a pharmacokinetic bridging study.
• The company is also advancing the XRx-008 program for ADPKD, with plans for a Phase 3 registration clinical trial.
• The company has received Orphan Drug Designation for XRx-008.
• The company is also developing XRx-101 for AKI associated with respiratory virus infections and XRx-225 for T2DN.
• The company is subject to laws and regulations affecting international trade and transactions.
• The company is also subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.
• The company is exposed to market risks resulting from fluctuations in foreign currency exchange rates.
• The company has no marketing and sales organization and has no experience in marketing prescription drug products.
• The company is a foreign private issuer and may have disclosure obligations that are different from those of U.S. domestic reporting companies.
• The company is an emerging growth company, and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth companies could make our Common Shares less attractive to investors.
• The company may be subject to U.S. civil liabilities that may not be enforceable against us, our directors, our officers or certain experts named in this Annual Report.
• The company's bylaws provide that any derivative actions, actions relating to breach of fiduciary duties and other matters relating to our internal affairs will be required to be litigated in Canada, which could limit shareholders ability to obtain a favorable judicial forum for disputes with us.
• The company's U.S. holders of the Companys shares may suffer adverse tax consequences if we are characterized as a passive foreign investment company.
• The company's share price is likely to be volatile and the market price of our Common Shares may drop.
• The company incurs significant costs as a result of operating as a public company and our management is required to devote substantial time to corporate governance standards.
• The company relies on third parties to monitor, support, conduct and oversee clinical trials of the product candidates that we are developing and, in some cases, to maintain regulatory files for those product candidates.
• The company faces significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
• The company's commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.
• The company may become involved in lawsuits to protect or enforce our patents and trade secrets, which could be expensive, time consuming and unsuccessful.
• The company may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
• The company depends on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights progress in drug development programs and regulatory interactions, it also acknowledges significant risks and financial challenges, including ongoing losses and the need for additional funding.

Positives

• The company is prioritizing the XRx-026 program for gout, aiming for NDA submission.
• The company is planning a pharmacokinetic bridging study to support the XRx-026 NDA.
• The company is planning a Phase 3 registration clinical trial for XRx-008 in ADPKD.
• The company has received Orphan Drug Designation for XRx-008.

Negatives

• The company is subject to U.S. civil liabilities that may not be enforceable against us, our directors, our officers or certain experts named in this Annual Report.
• The company's bylaws provide that any derivative actions, actions relating to breach of fiduciary duties and other matters relating to our internal affairs will be required to be litigated in Canada, which could limit shareholders ability to obtain a favorable judicial forum for disputes with us.
• The company's U.S. holders of the Companys shares may suffer adverse tax consequences if we are characterized as a passive foreign investment company.
• The company's share price is likely to be volatile and the market price of our Common Shares may drop.
• The company incurs significant costs as a result of operating as a public company and our management is required to devote substantial time to corporate governance standards.
• The company relies on third parties to monitor, support, conduct and oversee clinical trials of the product candidates that we are developing and, in some cases, to maintain regulatory files for those product candidates.
• The company faces significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
• The company's commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.
• The company may become involved in lawsuits to protect or enforce our patents and trade secrets, which could be expensive, time consuming and unsuccessful.
• The company may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
• The company depends on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.

Risks

• The company will require substantial additional funding, which may not be available on acceptable terms, or at all, and, if not available, may require us to alter, delay, scale back, or cease our product development programs or operations.
• The company has incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future.
• The company has not generated any revenue to date and may never be profitable.
• The company has a limited number of product candidates, all of which are still in preclinical or clinical development, and we may fail to obtain regulatory approval or experience significant delays in doing so.
• The company's product candidates may have undesirable side effects that may delay or prevent marketing approval or, if approved, require them to be taken off the market, require them to include contraindications, warnings and precautions, limitations of use, or otherwise limit their sales.
• The company may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements, and the denial or delay of any such approval would delay commercialization of our product candidates, if approved, and adversely impact our potential to generate revenue, our business and our results of operations.
• Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or protected health information or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
• The company's existing strategic partnerships are important to our business, and future strategic partnerships may also be important to us; if we are unable to maintain any of these strategic partnerships, or if these strategic partnerships are not successful, we may not realize the anticipated benefits of our strategic partnerships and our business could be adversely affected.
• The company relies on third parties to monitor, support, conduct and oversee clinical trials of the product candidates that we are developing and, in some cases, to maintain regulatory files for those product candidates.
• The company faces significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.
• The company's commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.
• The company may become involved in lawsuits to protect or enforce our patents and trade secrets, which could be expensive, time consuming and unsuccessful.
• The company may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
• The company depends on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.

Future Outlook

XORTX intends to advance its XRx-026 program for gout and XRx-008 program for ADPKD, while also pursuing non-dilutive and dilutive funding and exploring partnerships with major pharmaceutical companies.

Industry Context

The announcement reflects the ongoing efforts in the pharmaceutical industry to develop treatments for kidney diseases and gout, with a focus on addressing unmet medical needs and improving patient outcomes. The company is positioning itself to compete with existing therapies and emerging treatments in these areas.

Comparison to Industry Standards

• The company is pursuing a 505(b)(2) regulatory pathway, which is a common strategy for companies developing new formulations of existing drugs.
• The company is also pursuing Orphan Drug Designation, which is a common strategy for companies developing treatments for rare diseases.
• The company is competing with companies such as Takeda and Otsuka Pharmaceuticals, which have existing therapies for gout and ADPKD, respectively.
• The company is also competing with companies developing new therapies for gout and ADPKD, such as bardoxolone, venglustat, and GLPG2737, RGLS4326 and NV-20494.

Management Changes

Related Party Transactions

• Wages and benefits and professional fees were paid or accrued to Allen Davidoff, CEO, in the amount of $391,655.
• Professional fees were paid or accrued to Michael Bumby, CFO, in the amount of $6,515 and to 1282803 Ontario Inc., a company owned by Jim Fairbairn, former CFO of the Company in the amount of $149,820.
• Research and development fees were paid or accrued to Haworth Biopharmaceutical, a company owned by Stephen Haworth, CMO of the Company in the amount of $110,445.
• Consulting fees were paid or accrued to Stacy Evans, CBO of the Company in the amount of $157,500.
• Directors fees were paid or accrued to the directors of the Company in the amount of $172,229. The amount includes a directors fee payment of $123,133 for the year ended December 31, 2024 to Anthony Giovinazzo, Chairman of the Company.
• As of December 31, 2024, $11,120 was payable to directors of the Company, $7,705 was payable or accrued to the CFO of the Company for CFO services, $8,000 was payable and accrued to the CMO of the Company for consulting services, and $12,500 was payable and accrued to the CBO of the Company for consulting services.

Stakeholder Impact

• Shareholders are subject to risks associated with the speculative nature of the investment, potential dilution, and market fluctuations.
• Employees and consultants are subject to insider trading policies and may be affected by changes in management or strategic direction.
• Patients with gout, ADPKD, T2DN, and AKI may benefit from the development of new therapies.
• The company's success depends on maintaining relationships with strategic partners, suppliers, and contract research organizations.

Next Steps

• Submit a Type C meeting request with the FDA for the XRx-026 program.
• Initiate commercial supply of drug product for XRx-026.
• Prepare an NDA for submission in fiscal 2025 for XRx-026.
• Enter discussions with potential marketing and selling partners in the US and in other major global markets for XRx-026.
• Prepare for commercialization of XRx-026 in late 2026.
• Initiate the XRX-OXY-201 Clinical Trial for XRx-008 in the first half of 2025.
• Prepare and communicate with the FDA and EMA regarding a second phase clinical trial named XRX-OXY-301, a Full Registration trial in ADPKD.
• Focus on scale-up, validation and stability testing of clinical drug product supplies of XORLOTM under the Companys granted IND.
• Conduct commercialization studies to support in-depth analysis of pricing and/or reimbursement, as well as evaluate product brand name selection and prepare related filings and conduct other launch preparation activities.
• Continue to work with and seek out guidance from the EMA to facilitate the path to potential approval of its XRx-026 and XRx-008 programs in the EU, including required clinical studies and reimbursement conditions.

Key Dates

Keywords

XORTX Therapeutics, gout, ADPKD, AKI, T2DN, XRx-026, XRx-008, XRx-101, XRx-225, FDA, clinical trials, pharmaceutical, Orphan Drug Designation, kidney disease, oxypurinol